Design, synthesis and microbiological evaluation of ampicillin–tetramic acid hybrid antibiotics

Philip T Cherian1, Aditi Deshpande2,4, Martin N Cheramie1,4, David F Bruhn1, Julian G Hurdle2,3 and Richard E Lee1

Exploiting iron-uptake pathways by conjugating β-lactam antibiotics with iron-chelators, such as catechol and hydroxamic acid is a proven strategy to overcome permeability-related resistance in Gram-negative bacteria. As naturally occurring iron-chelating tetramic acids have not been previously examined for this purpose, an exploratory series of novel ampicillin–tetramic acid hybrids that structurally resemble ureidopenicillins was designed and synthesized. The new analogs were evaluated for the ability to chelate iron and their MIC activities determined against a representative panel of clinically significant bacterial pathogens. The tetramic acid β-lactam hybrids demonstrated a high affinity to iron in the order of $10^{-30}$ M$^3$. The hybrids were less active against Gram-positive bacteria. However, against Gram-negative bacteria, their activity was species dependent with several hybrids displaying improved activity over ampicillin against wild-type Pseudomonas aeruginosa. The anti-Gram-negative activities of the hybrids improved in the presence of clavulanic acid revealing that the tetramic acid moiety did not provide added protection against β-lactamases. In addition, the hybrids were found to be efflux pump substrates as their activities markedly improved against pump-inactivated strains. Unlike the catechol and hydroxamic acid siderophore β-lactam conjugates, the activities of the hybrids did not improve under iron-deficient conditions. These results suggest that the tetramic acid hybrids gain permeability via different membrane receptors, or they are outcompeted by native bacterial siderophores with stronger affinities for iron. This study provides a foundation for the further exploitation of the tetramic acid moiety to achieve novel β-lactam anti-Gram-negative agents, providing that efflux and β-lactamase mediated resistance is addressed.

The Journal of Antibiotics (2017) 70, 65–72; doi:10.1038/ja.2016.52; published online 18 May 2016

INTRODUCTION

β-lactam antibiotics are the leading marketed drugs for the treatment of bacterial infections, but resistance to this class of agents is now common in both Gram-positive and Gram-negative pathogens.1,2 The underlying mechanisms of resistance include production of β-lactamases that hydrolyze the lactam ring, alterations within the penicillin-binding protein binding site that reduce antibiotic affinity, changes in outer-membrane permeability that decrease antibiotic uptake and increased expression of efflux pumps that reduce target access.3 Studies have shown that permeability-mediated resistance can be overcome by exploiting the iron-uptake pathways as a Trojan horse strategy to enter antibiotics into bacterial cells.4 Bacteria assimilate iron by synthesizing and utilizing low molecular weight iron-chelating compounds called siderophores, and these Fe$^{3+}$–siderophore complexes are recognized and actively transported into cells by siderophore receptors located in the outer membrane.5 Iron uptake mechanisms are particularly active in hosts where freely available iron in tissue fluids is scarce. Hence, conjugating antibiotics to siderophores presents an attractive approach to promote the cellular uptake of antibiotics.

This strategy has been successfully applied to improve the in vitro activity of ampicillin and amoxicillin against Gram-negatives, including Pseudomonas aeruginosa.6,7 Also, novel monobactam antibiotics containing a siderophoric motif were shown to utilize the iron-uptake pathway to enter cells; these compounds also display efficacy in animal models of Gram-negative infections.8–10

The most common siderophores belong to three main classes: catecholates, hydroxamates and α-hydroxycarboxylates.11 Of these, the catecholates and hydroxamates have been widely explored in antibiotic drug discovery.12 One iron chelator moiety that appears to be underutilized is the class of natural products known as tetramic acids. Tetramic acid motifs are found in a wide variety of pharmacologically active natural products, with many displaying antifungal and antibacterial activities.13–15 Molecules bearing the tetramic acid core demonstrate diverse modes of action ranging from inhibition of cell wall16 and RNA synthesis,17 and dissipation of the membrane potential.18 The tetramic acid motif has the ability to interact with acid and metal binding enzymatic domains in essential bacterial drug targets.19,20 However, there are no marketed antibiotics containing the
tetramic acid motif. The 3-carbonyl tetramic acids are strongly acidic with pKa ~ 2.3–3.5, and they chelate a variety of metal ions, such as Fe^{3+}, Zn^{2+}, Ca^{2+}, Mg^{2+} and Cu^{2+}.21,22 Recently, the tetramic acid harzianic acid was described as a novel siderophore in *Trichoderma harzianum*.23 Similarly, based on studies by Kauffman et al.24 it is thought that physiological degradation of the quorum-sensing molecule N-acylhomoserine lactones to a tetramic acid may play a role in iron acquisition by *P. aeruginosa*. Although several known siderophore moieties have been applied in discovering siderophore-fused β-lactam antibiotics, there is a lack of literature examining the use of the tetramic acid motif for cellular drug uptake. Considering these factors, we sought to examine the prospect of applying the tetramic acids motif to β-lactam antibiotics. We hypothesized that attaching a 3-acyltetramic acid moiety to β-lactam antibiotics could improve their activity by increasing permeability by exploiting the metal ion-uptake pathways. As ampicillin has been successfully linked to other siderophores, we tested our hypothesis herein by synthesizing an exploratory series of novel ampicillin–tetramic acid hybrids, similar in molecular shape to ureidopenicillins, and examined their antimicrobial activities.

RESULTS AND DISCUSSION

Design of ampicillin–tetramic acid hybrids

The amine terminal of ampicillin was selected for the attachment of the tetramic acid motif based on the structures of previously reported ampicillin–siderophore conjugates where catecholate siderophores were attached to this position through acylation.6,7 These conjugates contained more than one catechol moieties attached to ampicillin via linkers of varying lengths (Figure 1a). For our study, we decided to attach the tetramic acid directly to the amine terminal of ampicillin, which was inspired by the observation that this amine is acylated to form a urea in the ureidopenicillins, such as piperacillin. Ureidopenicillins show broad-spectrum activity against Gram-positive and Gram-negative bacteria including most notably *P. aeruginosa*.25–27 It was also noted that an acidic center was also tolerated at this position, as replacement of the ampicillin amine by a carboxylic group produces carbenicillin. Carbenicillin displays significant Gram-negative coverage including strain dependent antipseudomonal activity.28,29 The tetramic acid core offers several potential positions for attachment to the ampicillin amine. The 3-position was selected for attachment of ampicillin for synthetic ease and overall pharmacophoric match.30,31 Accordingly, we designed ampicillin–tetramic acid hybrids in which ampicillin was linked to the 3-position of tetramic acid via a carboxamide (Figure 1b). This design combined the structural features of both ureidopenicillins and carbenicillin while introducing a chelating tetramic acid. Based on this design, a small library of analogs was synthesized to study the structure–activity relationship (Figure 2). The intermediate 3-methoxy carbonyl tetramic acids were synthesized from various amino acids creating diversity at the C5 and N1-positions of the tetramic acid core. These structural modifications allowed us to explore the influence of different physicochemical parameters, such as of size, shape, hydrophobicity and polarity on the activity of the hybrids. The hybrids were synthesized as shown in Scheme 1. The NMR characterization of 3-carbonyl tetramic acids can be complicated due to their ability to undergo keto–enol tautomerism. A total of nine tautomers are possible, but typically only four enolic tautomers are observed in solution (Figure 3).15,16 These tautomers form two pairs of internal tautomers (a ⇄ b and c ⇄ d) which are in rapid equilibrium and a pair of external tautomers (ab ⇄ cd), which is in slow equilibrium. The interconversion of the external tautomers is postulated to proceed via the β-triketo tautomer c.17 The ratio of the tautomers observed during NMR analysis can be influenced by the solvent.33 In our study, the NMR for all hybrid molecules were performed in MeOH-d4 and they all displayed only one major tautomer, which is tautomer a.

Antimicrobial activity against Gram-positive bacteria in Mueller–Hinton broth

In order to determine the antimicrobial potential of these hybrids, they were initially tested against a panel of Gram-positive and Gram-negative bacteria in cation-adjusted Mueller–Hinton (MH) broth, with below MICs being mean values of at least two replicates. In general, against Gram-positive bacteria (Table 1), the fusion of ampicillin with tetramic acid led to a moderate loss in potency. Nevertheless, several hybrids displayed good activity with low MICs (<0.2–6.25 μg ml⁻¹) against methicillin-sensitive *S. aureus* (MSSA), *Streptococcus pyogenes*, *S. pneumoniae* and *Bacillus anthracis* sterne and *B. subtilis*. Against *Enterococcus faecalis* and methicillin-resistant *S. aureus*, most hybrids had MICs >25 μg ml⁻¹. Previously, we reported that the antimicrobial activity of tetramic acids belonging to the membrane active reutericyclin class was influenced by hydrophobic substituents at the N1, C5 and 3-positions of the tetramic core, and that the simple hydrophobic tetramic acid alone did not possess measurable antibacterial activity (MICs >200 μg ml⁻¹) against Gram-positive bacteria.18,34 In comparison, for tetramic acid–ampicillin hybrids, different substituents at the C5 and N1-positions on the tetramic core, irrespective of their size, shape, hydrophobicity and polarity produced similar activity, and no clear structure–activity relationship was observed. In addition, the position of the substituent (C5 or N1) did not affect the activity, for example, 2746 and 2742, which have a methyl group at the C5 and N1-position respectively have comparable activity; similarly, 2745 and 2919, which have a phenyl group at the C5 and N1-positions, respectively, have comparable activity. The lack of structure–activity relationship and loss of potency compared to ampicillin might suggest suboptimal binding of these hybrids with target penicillin-binding proteins; however, due to the chelating nature of tetramic acids, the possibility that these hybrids may be functioning via mechanism(s) unrelated to penicillin-binding protein cannot be ruled out. Although cytotoxicity is a concern for tetramic acid bearing molecules, such as some reutericyclins, we investigated this property in the ampicillin–tetramic acid hybrids.14,34 When tested against HeLa cells, the hybrids were non-toxic producing cytotoxicity values similar to other penicillin antibiotic controls (Supplementary Table S1).

Antimicrobial activity against Gram-negative bacteria in Mueller–Hinton broth

Compounds within the tetramic acid class (for example, reutericyclins) are typically inactive against the Gram-negative test panel in Table 2.15,18,34 However, against the panel of type strains of Gram-negative bacteria, fusion of ampicillin with tetramic acid produced variable effects against the different species (Table 2), with a general observed trend that some hybrids showed increased activity over ampicillin and carbenicillin, but were inferior to piperacillin for some key species. Best results were observed against *P. aeruginosa*, where the activities of the hybrids were four–sixteen-fold better than ampicillin (>200 μg ml⁻¹) and two–eightfold over carbenicillin. The most active compounds 1905, 2731 and 3002 showed MIC of 12.5 μg ml⁻¹, which is twofold less active than piperacillin (6.25 μg ml⁻¹). Against *Acinetobacter baumannii*, the MICs ranged from 25–100 μg ml⁻³, with the exception of 1905, 2746 and 2780 (>200 μg ml⁻¹); the compounds were generally better than ampicillin and carbenicillin (100 μg ml⁻¹).
but were at least fourfold less active than piperacillin (6.25 μg ml⁻¹). Against *Klebsiella pneumoniae*, the hybrids displayed weaker activities (≥200 μg ml⁻¹) compared to ampicillin (100 μg ml⁻¹), carbenicillin (50 μg ml⁻¹) and piperacillin (6.25 μg ml⁻¹). Several hybrids displayed low MICs against *Proteus mirabilis* (1.56–25 μg ml⁻¹) and were comparable to ampicillin (3.13 μg ml⁻¹) and carbenicillin (1.56 μg ml⁻¹) but inferior to piperacillin (0.19 μg ml⁻¹). Against the ampicillin-resistant *P. vulgaris*, 2744–45, 2780–82 and 2916–18 (6.25–12.5 μg ml⁻¹) displayed improved activities over ampicillin and carbenicillin (100 μg ml⁻¹) but these were not better than piperacillin (1.56 μg ml⁻¹). Against *E. coli* BW25113, the most active hybrids were 2917, 2918, 2919 and 3002, which had MICs of 6.25–12.5 μg ml⁻¹ that was either comparable to piperacillin (6.25 μg ml⁻¹) or slightly inferior to ampicillin (3.13 μg ml⁻¹). Other compounds in the series displayed MICs of 25–200 μg ml⁻¹, which was comparable to carbenicillin (100 μg ml⁻¹). In order to determine whether the introduction of tetramic acid-rendered ampicillin more susceptible to exclusion via efflux pumps, we tested the compounds against an *E. coli* BW25113 strain that lacked tolu, an important part of the AcrAB–ToIC multi-drug efflux system. The hybrids displayed dissimilar MIC activities against both *E. coli* BW25113 and the TolC-deficient strain, suggesting that they are substrates for the TolC-based efflux systems, such as the AcrAB–ToIC pump. For instance, 2916 which has MIC of 50 μg ml⁻¹ against *E. coli* BW25113 showed a significantly reduced MIC of 1.56 μg ml⁻¹ in the TolC-deficient strain (Table 2). These shifts are also observed for piperacillin and carbenicillin. These results suggest that efflux is a key factor dictating the relative activities of compounds in the series.

Activity against Gram-negative bacteria in the presence of clavulanic acid

In order to determine whether the activity of these hybrids is affected by β-lactamases, their activity was determined in the presence of sub-inhibitory levels of clavulanic acid (6 μg ml⁻¹; Table 3 and Supplementary Table S2). In the presence of clavulanic acid, hybrids displayed improved activities against wild-type *E. coli* BW25113 with MIC activities comparable to the isogenic strain lacking chromosomally encoded β-lactamase AmpC. Improvement in MIC activity was also observed against *P. aeruginosa* in the presence of clavulanic acid with many hybrid compounds showing activity in the 3.1–6.3 μg ml⁻¹ range. Against *E. coli* ATCC 35218, expressing the TEM-1 β-lactamase, clavulanic acid improved the activity of piperacillin, ampicillin, and compounds in the series with the exception of 2742, 2743 and 2746 (Supplementary Table S2). For example, in the presence of clavulanic acid activities of 2781, 2782 and 2916 were 25 μg ml⁻¹ compared to >200 μg ml⁻¹ in its absence. However, both the hybrids and control drugs did not show any activity against a panel of organisms expressing multiple β-lactamas (for example, CTX-M-14, KPC-3 and VIM-1) suggesting that they are substrates for these and likely other β-lactamas (Supplementary Table S2).

Comparison of compound activities under iron-depleted media

Unlike laboratory media, iron is not freely available in the body. 35 Hence, testing of β-lactam-siderophore conjugates under iron-depleted conditions improves the activity of these agents due to their increased cellular uptake via siderophore transporters, which are more highly expressed under these conditions. 36 This led us to explore if tetramic acid chelation of metal ions may alter cellular uptake and
whether testing in iron-depleted MH media could enhance their activity. We first confirmed that the compounds chelate ferric ion. The addition of iron (III) chloride to resulted in the formation of an intense red to brown color consistent with the formation of a tetramic acid–iron complex. The stoichiometry of 3:1 tetramic acid: iron for the complex was determined by the continuous variation method (Supplementary Figure S1). Next, we tested the activity of these hybrids in iron-deficient conditions with 2,2'-bipyridyl (30 μg ml⁻¹) to increase the expression of siderophore transporters. A significant increase in siderophore production was confirmed in the test media for P. aeruginosa and E. coli (Supplementary Table S3), which suggests an increase in cognate siderophore receptors and other transporters for iron uptake. Under iron-depleted conditions, 2916 and other test compounds either showed no change in activities or exhibited only a two–fourfold difference in activities (Table 4). The trend in the broth MICs for the compounds against P. aeruginosa and E. coli strains was also evident from agar diffusion tests (Supplementary Table S4). It was hypothesized that bacterial siderophores with higher affinity than
Table 1 MIC (µg ml⁻¹) of ampicillin–tetramic acid hybrids against Gram-positive bacteria

| Compound | EF | SR | SP | BA | BS | MSSA | MRSA |
|----------|----|----|----|----|----|------|------|
| Ampicillin | 3.13 | <0.2 | <0.2 | <0.2 | <0.2 | <0.2 | 50 |
| Piperacillin | 3.13 | <0.2 | <0.2 | 0.39 | 0.39 | <0.2 | 25 |
| Carbenicillin | 3.13 | <0.2 | <0.2 | <0.2 | <0.2 | <0.2 | 6.25 |
| 1903 | 25 | 0.39 | 0.39 | 3.13 | 1.56 | 0.78 | 50 |
| 1905 | 50 | 0.78 | <0.2 | 3.13 | 1.33 | 0.78 | 50 |
| 1940 | 25 | 0.78 | 0.78 | 3.13 | 1.33 | 1.56 | 25 |
| 2742 | 25 | 1.56 | 1.56 | 6.25 | 3.13 | 1.56 | 100 |
| 2743 | 12.5 | <0.2 | <0.2 | 0.78 | 0.78 | 0.78 | 25 |
| 2744 | 12.5 | 0.78 | 0.78 | 6.25 | 3.13 | 1.56 | 25 |
| 2745 | 12.5 | 0.78 | 0.78 | 6.25 | 3.13 | 0.78 | 25 |
| 2746 | 25 | 0.39 | 0.39 | 1.56 | 0.78 | 1.56 | 25 |
| 2780 | 25 | 0.78 | 0.39 | 1.56 | 0.78 | 0.78 | 50 |

Abbreviations: BA, B. anthracis stearne; BS, B. subtilis ATCC23387; EF, E. faecalis ATCC33186; MRSA, S. aureus NRS 70; MSSA, S. aureus ATCC29213; SP, S. pneumoniae R6; SPy, S. pyogenes ATCC700294.

Table 2 MIC (µg ml⁻¹) of ampicillin–tetramic acid hybrids against Gram-negative bacteria

| Compound | AB | EC | ECαtOC | PV | PM | KP | PA |
|----------|----|----|--------|----|----|----|----|
| Ampicillin | 100 | 3.13 | 3.13 | 100 | 3.13 | 100 | >200 |
| Piperacillin | 6.25 | 6.25 | 1.56 | 1.56 | 0.19 | 6.25 | 6.25 |
| 1903 | 50 | 50 | 6.25 | 25 | 12.5 | 200 | 12.5 |
| 1905 | 200 | 200 | 6.25 | 50 | 25 | 250 | 200 |
| 2742 | 100 | 100 | 12.5 | 6.25 | >200 | 25 |
| 2743 | 50 | 200 | 12.5 | 100 | 3.13 | >200 | 25 |
| 2744 | 50 | 100 | 3.13 | 12.5 | 12.5 | >200 | 25 |
| 2745 | 50 | 100 | 3.13 | 12.5 | 12.5 | >200 | 25 |
| 2746 | 200 | 200 | 12.5 | 100 | 3.13 | >200 | 50 |
| 2780 | >200 | 200 | 6.25 | 12.5 | 1.56 | >200 | 25 |
| 2781 | 50 | 100 | 3.13 | 6.25 | 3.13 | >200 | 12.5 |
| 2782 | 25 | 25 | 1.56 | 12.5 | 1.56 | >200 | 25 |
| 2833 | 25 | 100 | 3.13 | 100 | 6.25 | 200 | 25 |
| 2835 | 50 | 100 | 3.13 | 25 | 25 | 200 | 25 |
| 2836 | 50 | 100 | 1.56 | 6.25 | 6.25 | >200 | 25 |
| 2917 | 50 | 12.5 | 6.25 | 6.25 | 3.1 | >200 | 25 |
| 2918 | 100 | 6.25 | 6.25 | 6.25 | 6.25 | >200 | 50 |
| 3002 | 25125 | 6.25 | 6.25 | 25 | 1.56 | 200 | 12.5 |

Abbreviations. AB, A. baumannii ATCC 19606; EC, E. coli BW25113; ECαtOC, E. coli BW25113 atOC derivative JW5503-1; KP, K. pneumoniae ATCC 13883; PA, P. aeruginosa PA01; PV, P. mirabilis ATCC 25933; PV, P. vulgaris ATCC 33420.

tetramic acids for iron might be limiting the activity of these hybrids. Thus, the apparent binding constant (Kₐb_app) of 2916 for iron (III) was measured as 0.55 × 10⁻⁵ M⁻¹ by monitoring the loss of absorbance of 2916–iron (III) complex at 460 nm in presence of increasing concentrations of EDTA (Supplementary Figure S2), which is similar to the previously reported values for tetramic acids.²⁴ As in this experiment iron affinity of bidentate chelating tetramic acids is being compared to hexadentate bacterial siderophores, the parameter pM was also calculated for the binding for comparative purposes.⁴² The pM value is expressed as −log [Fe³⁺], where [Fe³⁺] is the free iron concentration in the presence of 10⁻⁵ M total iron chelator and 10⁻⁵ M total Fe³⁺ at pH 7.4. A larger pM value indicates a more effective ligand under the given conditions. Using this equation, the pM for 2916 was calculated to be 20.3. Thus, although the tetramic acid hybrids (K₉ 0.55×10⁻⁵ M¹ and pM 20.3) may compete favorably with weak iron-chelating siderophores, such as pyochelin (K₉ 10⁻⁵ M¹ and pM 6),⁴³,⁴⁴ they will likely be outcompeted by siderophores with larger pM values, such as P. aeruginosa pyoverdin (K₉ 10⁻² M¹ and pM 27)⁴⁵-⁴⁶ or E. coli enterobactin (K₉ 10⁻⁵ M¹ and pM 36).⁴⁴ Further, the affinities of tetramic acid for the membrane receptors of siderophores and iron uptake transporters are unknown. To explore these hypotheses, we tested the hybrid compounds against P. aeruginosa and E. coli mutants in which siderophore receptors or siderophores were inactivated by single gene deletions. This data is presented in Supplementary Tables S5 and S6. In summary, deletion on the TonB protein in both species did not influence the activity of compounds; TonB plays a key role in the periplasmic uptake of siderophores as it interacts with several siderophore receptors to provide energy for transport.⁴⁷ The loss of enterobactin biosynthesis protein (ΔentB), the ferrienterobactin permease, and other iron transporters did not affect the activity of the compounds against E. coli. Similarly, against P. aeruginosa, the loss of pyoverdin biosynthesis (Δpvca)⁴⁸ and pyoverdin receptors (for example, ΔfpnA; ΔfpvB)⁴⁹,⁵⁰ did not affect the activities of the compounds. Together this suggests that the activities of the compounds are not influenced by siderophore competition and point to an alternate mechanism of uptake. In light of the compounds appearing as substrates for efflux pumps, we determined if the efflux pump inhibitor CCCP could enhance the activity of compounds against P. aeruginosa and E. coli. CCCP dissipates the bacterial proton motive force, leading to the inhibition of several efflux pumps.⁵¹ As shown in Table 4, the addition of CCCP also significantly improved the activities of the compounds by two–eightfold against P. aeruginosa and two–sixteenfold against E. coli.

Conclusions
Our strategy for improving the activity of the β-lactam antibiotic ampicillin by fusing its amine terminal with iron-chelating tetramic acids produced compounds with weak to moderate antibacterial activities. Compounds in this series were identified with improved activity against P. aeruginosa. The P. aeruginosa quorum-sensing signal N-3-oxododecanoyl-L-homoserine degrades under physiological conditions to produce a tetramic acid. The role of the rearranged tetramic acid product is not yet clear, but it has been proposed to play a function in iron acquisition.²⁴ Other β-lactams siderophore conjugates have been reported to utilize cognate siderophore receptors for entry through the outer Gram-negative membrane. However, tetramic acids are in a different chemical class to hydroxamates and catechols that are typically utilized in siderophore drug conjugates. These conjugates must be recognized by specific outer-membrane receptors whose expression levels are highest when iron concentrations are low. The activity of the tetramic acids β-lactam hybrids is independent of media iron concentration and hence we speculate that they use a different receptor or porin to enter P. aeruginosa. Future elucidation of this receptor or uptake mechanism could lead to compounds that are optimized to gain entry into P. aeruginosa and other Gram-negative pathogens. In addition, key limitations of the
### Table 3 MIC (μg ml⁻¹) of ampicillin–tetramic acid hybrids against Gram-negative bacteria in presence of clavulanic acid

| Compounds       | EC (6 μg ml⁻¹) | KP | EC+aampC | PA |
|-----------------|---------------|----|----------|----|
| Ampicillin      | 1.56          | 25 | 3.13     | 25 |
| Piperacillin    | 3.13          | 6.25| 6.25     | 6.25|
| 1903            | 12.5          | 50 | 100      | 12.5|
| 1905            | 200           | 100| 12.5     | 12.5|
| 1940            | 6.25          | 6.25| 6.25     | 6.25|
| 2742            | 200           | 25 | 100      | 125|
| 2743            | 200           | 25 | 25       | 12.5|
| 2744            | 12.5          | 25 | 100      | 25 |
| 2745            | 6.25          | 25 | 100      | 25 |
| 2764            | 12.5          | 25 | 200      | 50 |
| 2780            | 12.5          | 50 | 100      | 50 |
| 2781            | 6.25          | 50 | 100      | 50 |
| 2782            | 3.13          | 50 | 100      | 50 |
| 2833            | 12.5          | 100| 100     | 12.5|
| 2835            | 6.25          | 100| 100     | 12.5|
| 2916            | 12.5          | 100| 100     | 12.5|
| 2917            | 12.5          | 100| 100     | 12.5|
| 2918            | 12.5          | 25 | 50       | 12.5|
| 2919            | 6.25          | 25 | 50       | 12.5|

### Table 4 MIC (μg ml⁻¹) of ampicillin–tetramic acid hybrids against *P. aeruginosa* and *E. coli* in the presence of carbonyl cyanide m-chlorophenyl hydrazone and 2,2′-bipyridyl

| Compounds       | EC | EC+aampC |
|-----------------|----|----------|
| Ampicillin      | 3.13| 5.16     |
| Piperacillin    | 6.25| 6.25     |
| Carbenicillin   | 6.25| 6.25     |
| 1903            | 6.25| 6.25     |
| 1905            | 6.25| 6.25     |
| 1940            | 6.25| 6.25     |
| 2742            | 6.25| 6.25     |
| 2743            | 6.25| 6.25     |
| 2744            | 6.25| 6.25     |
| 2745            | 6.25| 6.25     |
| 2746            | 6.25| 6.25     |
| 2780            | 6.25| 6.25     |
| 2781            | 6.25| 6.25     |
| 2782            | 6.25| 6.25     |
| 2833            | 6.25| 6.25     |
| 2835            | 6.25| 6.25     |
| 2916            | 6.25| 6.25     |
| 2917            | 6.25| 6.25     |
| 2918            | 6.25| 6.25     |
| 2919            | 6.25| 6.25     |

### EXPERIMENTAL PROCEDURE

**Chemistry**

Details for the preparation of the ampicillin-tetramic acid hybrids are provided in the Supplementary Information. Briefly, various amino acid methyl esters were first acylated with methyl malonyl chloride and this intermediate was cyclized under Lacey-Deckmann condition to afford 3-methoxycarbonyl tetra-acids. Microwave heating of the 3-methoxycarbonyl tetra-acids with ampicillin in dimethylformamide at 100 °C for three minutes followed by purification by reverse phase column chromatography afforded the ampicillin–tetramic acid hybrids in 6–67% yields. The final compounds were characterized by LC–MS, 1H- and 13C-NMR. All reported compounds were ≥95% pure.

**Biology**

Determination of MICs in MH media. The MICs of compounds were determined in MH broth according to the Clinical Laboratory Standards Institute (CLSI), using the microbroth dilution method in 96-well round bottom plates. The bacterial inocula were prepared by growing colonies from MH agar in MH broth. The final test concentration of compounds ranged from 200-0.2 μg ml⁻¹ and bacterial inocula of 10⁵ CFU ml⁻¹. After incubation at 37 °C for 18–20 h the MICs were recorded as the lowest concentration of test compound inhibiting visible growth. 34 MICs were also determined in the current series include susceptibility to efflux pumps and inactivation by β-lactamases. These liabilities may be addressed through combinations with efflux pump or β-lactamase inhibitors combined with future chemical optimization of the tetramic acid–β-lactam hybrids. Our study provides the first description of tetramic acid–β-lactam hybrids and suggests that further studies are required to determine the mechanism of entry to the periplasmic space to fully explore the utility of tetramic acids as Trojan horses in overcoming outer-membrane permeability-mediated resistance to β-lactam antibiotics.
presence of the β-lactamase inhibitor clavulanic acid (6 μg mL⁻¹). MICs were performed in at least duplicate and the mean MIC is reported.

**Determination of MICs in iron-depleted media.** MICs in iron-depleted media were similarly determined with the following exceptions. Bacteria were grown on MH agar containing 30 μg ml⁻¹ 2,2’-bipyridyl that chelates ferric iron.24 Bacterial inocula were then prepared by growing colonies in MB broth containing 2,2’-bipyridyl (30 μg ml⁻¹) to mid-logarithmic phase. MICs were then performed as above, but using MB broth that contained 2,2’-bipyridyl (30 μg ml⁻¹); to permit adequate iron chelation, the 2,2’-bipyridyl was added to broth at least 3 h before setting up MIC test. The MICs were read after 18–20 h as above. MICs under iron-replete conditions were also assessed in the presence of the proton pump inhibitor 50 μg ml⁻¹ carbonyl cyanide m-chlorophenyl (CCCP). MICs were performed in at least duplicate and the mean MIC is reported.

**Detection of siderophore production by CAS liquid assay.** The increased production of siderophores in iron-depleted media was determined using the reported chromo azuro S assay (CAS) liquid assay.25 The following organisms were used to test for siderophore production: *P. aeruginosa* PA01 and *E. coli* strains BW25113. The CAS reagent was prepared by adding 10 ml of 10 μM ferric chloride in hydrochloric acid (100 mM) to 590 ml of a 1 mM of aqueous solution of CAS. The Fe-CAS solution was added to 400 ml of a 2 mM aqueous hexadecyl-trimethyl-ammonium bromide to yield CAS-Fe-hexadecyl-trimethyl-ammonium bromide. Bacteria were grown for 18–20 h in MB broth with and without 2,2’-bipyridyl (30 μg ml⁻¹) and culture turbidity determined at 600 nm. Subsequently, supernatants were filtered through 0.2 μm PES membrane filters to remove bacteria. Supernatants (700 μl) were mixed with 350 μl of the CAS-Fe-hexadecyl-trimethyl-ammonium bromide reagent, incubated in the dark for an hour and absorbance recorded at 630 nm. The relative percentage of siderophore production was then calculated based on changes in absorbance readings as previously reported.25 Triplicate cultures were used and all data were normalized based on the turbidity of the corresponding cultures.

**Cytotoxicity assay.** The HeLa cell line was cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum in a humidified incubator (37 °C, 5% CO₂). Cells were cultured to semi-confluence, trypsinized, and collected by centrifugation. Washed cells were resuspended in fresh Dulbecco’s modified Eagle’s medium at about 10⁵ cells ml⁻¹ and dispensed into 96-well microtitre plates (100 μl well⁻¹). After overnight incubation at 37 °C, compounds were added at twofold serial dilutions of test compounds (512–0.2 μg ml⁻¹) and plates incubated for 48 h. Cytotoxicity was evaluated using Promega CellTitre Glo luminescence assay (Promega, Madison, WI, USA). IC₅₀ data were obtained from dose-response curves plotted using Graphpad prism 5 (Graphpad Software, Inc., La Jolla, CA, USA).

**Determination of antibiotic susceptibility by agar diffusion.** The susceptibility of bacteria to test compounds were also evaluated by the agar diffusion technique as described,24 with minor changes. Briefly, bacteria was cultured in low-iron MH broth and 100 μl of a 10⁶ CFU ml⁻¹ sample was spread onto MH agar that contained 2,2’-bipyridyl (30 μg ml⁻¹). The plates were allowed to dry, before antibiotics (50 μl; 0.2 μl) were added to wells that were prepared with a core borer (6.35 mm). The plates were incubated at 37 °C overnight and the diameter of zone of inhibition was measured (mm).

**CONFLICT OF INTEREST** The authors declare no conflict of interest.

**ACKNOWLEDGEMENTS** We thank Dr Karen Bush at Indiana University, Bloomington for providing the β-lactamase producing bacterial strains. *E. coli* mutants were from the Keio Collection at The Coli Genetic Stock Center, Yale, Connecticut, USA; *P. aeruginosa* mutants were from the PA Two-Allele Library, Manoal Lab, University of Washington, Seattle, USA. This work was funded by Grant 5R01AT006732 from the National Center for Complementary and Alternative Medicine at the National Institutes of Health, with additional funds from the American Lebanese Syrian Associated Charities (ALSAC), St Jude Children’s Research Hospital.
35 Ratledge, C. & Dover, L. G. Iron metabolism in pathogenic bacteria. *Annu. Rev. Microbiol.* **54**, 881–941 (2000).

36 Zheng, T. & Nolan, E. M. Enterobactin-mediated delivery of beta-lactam antibiotics enhances antibacterial activity against pathogenic *Escherichia coli*. *J. Am. Chem. Soc.* **136**, 9677–9691 (2014).

37 Lebun, M. H. et al. Relationships between the structure and the phytotoxicity of the fungal toxin tenuazonic acid. *Phytochemistry* **27**, 77–84 (1988).

38 Renny, J. S. et al. Method of continuous variations: applications of job plots to the study of molecular associations in organometallic chemistry. *Angew Chem. Int. Ed. Engl.* **52**, 11998–12013 (2013).

39 Carpenter, B. M., Whitmire, J. M. & Merrell, D. S. This is not your mother's repressor: the complex role of fur in pathogenesis. *Infect. Immun.* **77**, 2590–2601 (2009).

40 Ji, C., Miller, P. A. & Miller, M. J. Iron transport-mediated drug delivery: practical syntheses and in vitro antibacterial studies of tris-catecholate siderophore-aminopenicillin conjugates reveals selectively potent antipseudomonal activity. *J. Am. Chem. Soc.* **134**, 9898–9901 (2012).

41 Brown, M. F. et al. Pyridone-conjugated monobactam antibiotics with Gram-negative activity. *J. Med. Chem.* **56**, 5541–5552 (2013).

42 Carrano, C. J. & Raymond, R. N. Ferric ion sequestering agents. *J. Am. Chem. Soc.* **101**, 5401–5404 (1979).

43 Cox, C. D. & Graham, R. Isolation of an iron-binding compound from *Pseudomonas aeruginosa*. *J. Bacteriol.* **137**, 357–364 (1979).

44 Zheng, T. & Nolan, E. M. Siderophore-based detection of Fe(iii) and microbial pathogens. *Metallomics* **4**, 866–880 (2012).

45 Meyer, J. M. & Abdallah, M. A. The fluorescent pigment of *Pseudomonas fluorescens*: biosynthesis, purification and physicochemical properties. *Microbiology* **107**, 319–328 (1978).

46 Albrecht-Gary, A.-M. et al. Bacterial iron transport: coordination properties of pyoverdin PaA, a peptidic siderosphere of *Pseudomonas aeruginosa*. *Inorg. Chem.* **33**, 6391–6402 (1994).

47 Adams, H. et al. Interaction of TonB with the outer membrane receptor FpvA of *Pseudomonas aeruginosa*. *J. Bacteriol.* **188**, 5752–5761 (2006).

48 Drake, E. J. & Gulick, A. M. Three-dimensional structures of *Pseudomonas aeruginosa* PvcA and PvcB, two proteins involved in the synthesis of 2-isocyano-6,7-dihydroxycoumarin. *J. Mol. Biol.* **384**, 193–205 (2008).

49 Edgar, R. J. et al. Interactions between an anti-sigma protein and two sigma factors that regulate the pyoverdine signaling pathway in *Pseudomonas aeruginosa*. *BMC Microbiol.* **14**, 287 (2014).

50 Glysels, B. et al. FpvB, an alternative type I ferrisiderophore receptor of *Pseudomonas aeruginosa*. *Microbiology* **150**, 1671–1680 (2004).

51 Lomovskaya, O. et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in *Pseudomonas aeruginosa*: novel agents for combination therapy. *Antimicrob. Agents Chemother.* **45**, 105–116 (2001).

52 Mochizuki, H. et al. Bactericidal activity of M14659 enhanced in low-iron environments. *Antimicrob. Agents Chemother.* **32**, 1648–1654 (1988).

53 Dale, S. E. et al. Role of siderophore biosynthesis in virulence of *Staphylococcus aureus*: identification and characterization of genes involved in production of a siderophore. *Infect. Immun.* **72**, 29–37 (2004).

54 Wencewicz, T. A. et al. Trihydroxamate siderophore-fluoroquinolone conjugates are selective sideromycin antibiotics that target *Staphylococcus aureus*. *Bioconjug. Chem.* **24**, 473–486 (2013).

Supplementary Information accompanies the paper on The Journal of Antibiotics website (http://www.nature.com/ja)